found that tumor-initiating stem cells selectively express CD80, which inhibits T cell activity upon engagement with cytotoxic T lymphocyte antigen 4 (CTLA4), suggesting that blockade of these cells may repress cSCC recurrence (67). Here, CD80 is linked to neoplasm.